Certara, Inc. (NASDAQ:CERT) Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 32.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,351,604 shares of the company’s stock after selling 1,131,450 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in Certara were worth $27,537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. acquired a new position in Certara during the 2nd quarter worth about $26,000. Innealta Capital LLC acquired a new position in Certara in the second quarter valued at approximately $36,000. KBC Group NV lifted its position in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Certara in the 2nd quarter valued at about $152,000. Finally, Algert Global LLC purchased a new position in Certara during the 2nd quarter worth approximately $156,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Trading Down 0.5 %

Shares of CERT stock opened at $11.21 on Monday. The firm has a market capitalization of $1.80 billion, a PE ratio of -56.05, a price-to-earnings-growth ratio of 5.67 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a fifty day moving average of $10.81 and a two-hundred day moving average of $12.98. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the company posted $0.06 earnings per share. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling

In other news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the company. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. Robert W. Baird reduced their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Finally, Barclays dropped their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Certara currently has an average rating of “Hold” and an average price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.